vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-1210Research ArticleВ ПОМОЩЬ ВРАЧУA DOCTOR’S AIDРАННЯЯ ДИФФЕРЕНЦИАЛЬНАЯ ДИАГНОСТИКА И ДЛИТЕЛЬНАЯ ИММУНОМОДУЛИРУЮЩАЯ ТЕРАПИЯ ХРОНИЧЕСКИХ ВОСПАЛИТЕЛЬНЫХ ДЕМИЕЛИНИЗИРУЮЩИХ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ У ДЕТЕЙ И ПОДРОСТКОВEARLY DIFFERENTIAL DIAGNOSTICS AND PROLONGED IMMUNOMODULATORY THERAPY OF CHRONIC INFLAMMATORY DEMYELINATING DISEASES OF CENTRAL NERVOUS SYSTEM IN CHILDREN AND ADOLESCENTSБыковаО.В.BykovaO.V.ПлатоноваА.Н.PlatonovaA.N.ГольцоваН.В.Gol'tsovaN.V.КузнецоваГ.В.KuznetsovaG.V.КузенковаЛ.М.KuzenkovaL.M.БойкоА.Н.BoikoA.N.Научный центр здоровья детей РАМН, МоскваРоссияScientific Center of Children’s Health, Russian Academy of Medical Sciences, MoscowRussian FederationРоссийский государственный медицинский университет, МоскваРоссияRussian State Medical University, MoscowRussian Federation20092409201586Вопросы современной педиатрии139145Copyright © Быкова О., Платонова А., Гольцова Н., Кузнецова Г., Кузенкова Л., Бойко А., 20092009Быкова О., Платонова А., Гольцова Н., Кузнецова Г., Кузенкова Л., Бойко А.Bykova O., Platonova A., Gol'tsova N., Kuznetsova G., Kuzenkova L., Boiko A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/1210ReferencesBarkhof F., Polman C., Radue E.W. et al. Betaferon in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT): magnetic resonance imaging outcomes. 21-th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Greece. 2005. P. 583.Barkhof F., Polman C., Radue E.W. et al. Betaferon in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT): magnetic resonance imaging outcomes. 21-th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Greece. 2005. P. 583.Dale R.C., de Sousa C., Chong W.K. et al. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain. 2000; 123 (12): 2407–2422.Dale R.C., de Sousa C., Chong W.K. et al. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain. 2000; 123 (12): 2407–2422.Hahn C.D., Shroff M.M., Blaser S.I., Banwell B.L. MRI criteria for multiple sclerosis: evaluation in a pediatric cohort. Neurology. 2004; 62: 806–808.Hahn C.D., Shroff M.M., Blaser S.I., Banwell B.L. MRI criteria for multiple sclerosis: evaluation in a pediatric cohort. Neurology. 2004; 62: 806–808.Hynson J.L., Kornberg A.J., Coleman L.T. et al. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology. 2001; 56: 1308–1312.Hynson J.L., Kornberg A.J., Coleman L.T. et al. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology. 2001; 56: 1308–1312.Idrissova Z., Boldyreva M.N., Dekonenko E.P. et al. Acute disseminated encephalomyelitis in children: clinical features and HLA–DR linkage. Eur. J. Neurol. 2003; 10: 537–546.Idrissova Z., Boldyreva M.N., Dekonenko E.P. et al. Acute disseminated encephalomyelitis in children: clinical features and HLA–DR linkage. Eur. J. Neurol. 2003; 10: 537–546.Jacobs L.D., Beck R.W., Simon J.H. et al. CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N. Engl. J. Med. 2000; 343: 898–904.Jacobs L.D., Beck R.W., Simon J.H. et al. CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N. Engl. J. Med. 2000; 343: 898–904.Krupp L., Pohl D., Rostasy K. et al. CSF characteristics in early-onset multiple sclerosis. Neurology. 2004; 63: 1966–1967.Krupp L., Pohl D., Rostasy K. et al. CSF characteristics in early-onset multiple sclerosis. Neurology. 2004; 63: 1966–1967.Krupp Lauren B., Banwell B., Tenembaum S., for the International Pediatric MS Study Group. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology. 2007; 68: 7–12.Krupp Lauren B., Banwell B., Tenembaum S., for the International Pediatric MS Study Group. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology. 2007; 68: 7–12.Marchioni E., Ravaglia S., Piccolo G. et al. Postinfectious inflammatory disorders: subgroups based on prospective follow up. Neurology. 2005; 65: 1057–1065.Marchioni E., Ravaglia S., Piccolo G. et al. Postinfectious inflammatory disorders: subgroups based on prospective follow up. Neurology. 2005; 65: 1057–1065.McDonald W.I., Compston A., Edan G. et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001; 50: 121–127.McDonald W.I., Compston A., Edan G. et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001; 50: 121–127.Mikaeloff Y., Adamsbaum C., Husson B. et al. MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain. 2004; 127: 1942–1947.Mikaeloff Y., Adamsbaum C., Husson B. et al. MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain. 2004; 127: 1942–1947.Mikaeloff Y., Suissa S., Vallee L. et al. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J. Pediatr. 2004; 144: 246–252.Mikaeloff Y., Suissa S., Vallee L. et al. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J. Pediatr. 2004; 144: 246–252.Panitch H., Goodin D.S., Francis G. et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology. 2002; 59: 1496–1506.Panitch H., Goodin D.S., Francis G. et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology. 2002; 59: 1496–1506.Pittock S.J., Wingerchuk D.M., Krecke K. et al. Brain abnormalities in patients with neuromyelitis optica (NMO). Neurology. 2005; 64: 39.Pittock S.J., Wingerchuk D.M., Krecke K. et al. Brain abnormalities in patients with neuromyelitis optica (NMO). Neurology. 2005; 64: 39.Pohl D., Waubant E., Banwell B. et al. Treatment of pediatric multiple sclerosis and variants. Neurology. 2007; 68 (2): 54–65.Pohl D., Waubant E., Banwell B. et al. Treatment of pediatric multiple sclerosis and variants. Neurology. 2007; 68 (2): 54–65.Poser C.M., Paty D.W., Scheinberg L. et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983; 13: 227–231.Poser C.M., Paty D.W., Scheinberg L. et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983; 13: 227–231.Ruggieri M., Iannetti P., Polizzi A. et al. Multiple sclerosis in children under 10 years of age. Neurol. Sci. 2004; 25 (4): 326–335.Ruggieri M., Iannetti P., Polizzi A. et al. Multiple sclerosis in children under 10 years of age. Neurol. Sci. 2004; 25 (4): 326–335.Schumacker G.A., Beebe G., Kibler R.F. et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann. N.Y. Acad. Sci. 1965; 122: 552–568.Schumacker G.A., Beebe G., Kibler R.F. et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann. N.Y. Acad. Sci. 1965; 122: 552–568.Tenembaum S., Chamoles N., Fejerman N. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology. 2002; 59: 1224–1231.Tenembaum S., Chamoles N., Fejerman N. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology. 2002; 59: 1224–1231.Wingerchuk D.M., Pittock S.J., Lennon V.A. et al. Neuromyelitis optica diagnostic criteria revisited: Validation and incorporation of the NMO–IgG serum autoantibody. Neurology. 2005; 64: 38.Wingerchuk D.M., Pittock S.J., Lennon V.A. et al. Neuromyelitis optica diagnostic criteria revisited: Validation and incorporation of the NMO–IgG serum autoantibody. Neurology. 2005; 64: 38.Wingerchuk D.M., Weinshenker B.G. Neuromyelitis optica - Clinical predictors of a relapsing course and survival. Neurology. 2003; 60: 848–853.Wingerchuk D.M., Weinshenker B.G. Neuromyelitis optica - Clinical predictors of a relapsing course and survival. Neurology. 2003; 60: 848–853.Wingerchuk D.M. Acute disseminated encephalomyelitis: distinction from multiple sclerosis and treatment issues. Adv. Neurol. 2006; 98: 303–318.Wingerchuk D.M. Acute disseminated encephalomyelitis: distinction from multiple sclerosis and treatment issues. Adv. Neurol. 2006; 98: 303–318.
The authors declare that there are no conflicts of interest present.